This is a medicine used to treat malaria, an illness caused by a parasite. It works by stopping the parasite from multiplying. It's usually taken as a pill.
Every report comes from a Lived member, sent anonymously.
Have you tried Atovaquone for Pneumocystis Pneumonia (PCP)?
Atovaquone, sold in the US as Mepron oral suspension and as generic versions, is an antimicrobial medicine used mainly against Pneumocystis pneumonia (PCP). PCP is a lung infection caused by Pneumocystis jirovecii, a common fungus that rarely makes healthy people sick but can cause serious pneumonia in people with weakened immune systems, such as people with HIV, people who have had an organ or bone marrow transplant, and people taking chemotherapy or steroids. In the US, atovaquone is approved for adults and teenagers 13 and older in two situations: to prevent PCP, and to treat mild to moderate PCP, in people who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX, an antibiotic combination best known as Bactrim). TMP-SMX is the usual first choice, and atovaquone is an alternative when it causes an allergy or side effects a person cannot manage. Atovaquone has not been studied for severe PCP, which is treated differently. Doctors also use atovaquone together with the antibiotic azithromycin as the preferred treatment for babesiosis, a parasitic infection spread by ticks, and occasionally as a less-studied option for toxoplasmosis, an infection caused by the parasite Toxoplasma gondii. Atovaquone is also one of the two ingredients in Malarone (atovaquone and proguanil), a tablet used to prevent and treat malaria. Malarone is a separate product with its own dosing, and the two are not interchangeable.
Atovaquone is shaped much like ubiquinone, a molecule that microbes use inside their mitochondria, the structures that produce a cell's energy. Ubiquinone helps pass electrons along a chain of proteins, and several enzymes the organism needs depend on that chain. In malaria parasites, atovaquone blocks the chain at one step, which indirectly shuts down production of energy and of the building blocks for DNA, so the organism cannot grow. Exactly how it acts against Pneumocystis has not been fully worked out, although the same pathway appears to be the likely target. Atovaquone dissolves in fat rather than water, so the body absorbs it poorly on an empty stomach. In a label study, taking a dose after a meal increased the amount reaching the blood about 2.6-fold compared with fasting. The drug also leaves the body slowly, with a half-life of roughly three days, meaning about half of it is still present three days after a dose.
Atovaquone comes as a liquid suspension containing 750 mg in each 5 mL, supplied in bottles or single-dose foil pouches. For prevention, the usual dose for adults and teenagers is 10 mL (1,500 mg) once a day. For treating mild to moderate PCP, it is 5 mL (750 mg) twice a day for 21 days. Shake the bottle gently before each dose and measure with a dosing spoon or cup; a pouch is emptied completely, either straight into the mouth or into a spoon. Take every dose with food. This is the most important instruction for this medicine: without food, too little atovaquone reaches the blood, and in treatment studies people with low blood levels were more likely to have the treatment fail and to die. People who cannot eat reliably, or who have a digestive condition that limits how well they absorb medicines, may need a different medicine instead.
The most common side effects are diarrhea, nausea, vomiting, headache, rash and fever. In prevention studies, rash, diarrhea and nausea were the most frequent reasons people stopped taking it. Many people in those studies had advanced HIV, so some of these symptoms may have come from the illness rather than the drug. A rash deserves attention because atovaquone can rarely cause severe skin reactions. These include Stevens-Johnson syndrome, which blisters the skin and the linings of the mouth and eyes, and DRESS (drug reaction with eosinophilia and systemic symptoms), a widespread rash with fever and inflammation of internal organs. Stop the medicine and call the prescriber right away at the first sign of a new rash, sores in the mouth or eyes, or blistering or peeling skin. Swelling of the face, lips or throat, throat tightness, or wheezing and trouble breathing can mean a severe allergic reaction: call 911. Liver inflammation has been reported, and in rare cases fatal liver failure. Yellowing of the skin or eyes, or dark urine, should be reported to the prescriber promptly. Other rare problems reported since approval include methemoglobinemia (a blood change that reduces the oxygen red blood cells carry), low platelet counts, pancreatitis and kidney injury.
Rifampin and rifabutin, antibiotics used mainly for tuberculosis and related infections, lower atovaquone levels enough that the combination is not recommended. Tetracycline, another antibiotic, also lowers levels, so the care team watches for signs that atovaquone is not working if both are needed. Metoclopramide, an anti-nausea medicine, reduces absorption and is best avoided when another anti-nausea option will do. In the other direction, atovaquone lowers levels of indinavir, an older HIV medicine. Because people taking atovaquone are often on several medicines, the prescriber and pharmacist should review the full list, including HIV treatment and supplements. Anyone who has had a serious allergic or skin reaction to atovaquone should not take it again. People with severe liver disease need closer monitoring. Data from pregnancy are too limited to show whether atovaquone affects the baby, while PCP itself is dangerous during pregnancy, so the choice is made with the care team. There is no information on whether it passes into breast milk; for people with HIV, the risk of passing HIV to the baby through breastfeeding is also part of that discussion.
Treatment for active PCP lasts 21 days, and the care team follows fever, breathing and oxygen levels to make sure the infection is responding. Atovaquone involves a real trade-off compared with TMP-SMX: in the main head-to-head treatment study, atovaquone failed to control the infection more often (17% of people versus 6%), but far fewer people had to stop it because of side effects (7% versus 20%). That is why it is reserved for people who cannot take TMP-SMX, and why taking every dose with a meal matters so much. If the infection is not improving, the care team will switch to another treatment. For prevention, atovaquone is taken once a day for as long as the care team judges the risk of PCP to continue, which depends on the reason the immune system is weakened. In prevention studies it protected about as well as dapsone and inhaled pentamidine, two other alternatives to TMP-SMX. When atovaquone is combined with azithromycin for babesiosis, the usual course is 7 to 10 days, although people with severely weakened immune systems may need six weeks or longer.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Atovaquone, what you've noticed, or ask the community a question.